Patient Outcomes for Cyclophosphamide Treatment in Membranous Nephropathy

A retrospective cohort study from 2010 to 2022 analyzes 54 adult patients with primary membranous nephropathy treated with oral cyclophosphamide across the United States and India. The dataset, published by figshare admin karger, compares short-duration and long-duration treatment regimens, tracking remission rates and adverse events over a 12-month period.

Use Cases

• Compare overall_remission and complete_remission rates between short-duration and long-duration cyclophosphamide treatment groups.
• Analyze the relationship between cumulative_cyclophosphamide_dose (>3g vs. ≤3g) and clinical outcomes after adjusting for baseline_characteristics.
• Assess the incidence of serious_adverse_events across different treatment durations and patient subgroups.
• Investigate potential confounding factors, such as baseline_chronic_kidney_changes, on remission outcomes at the 12-month follow-up.

Strengths

• Multi-center data collection from the United States and India, providing a diverse patient cohort.
• Clear primary outcome (overall remission at 12 months) and secondary outcomes (complete remission, adverse events) defined for analysis.
• Analyses are stratified by both treatment_duration and cumulative_dose, allowing for nuanced investigation.

Limitations

• Small sample size of 54 patients, limiting statistical power and generalizability of findings.
• Retrospective study design is susceptible to selection bias and unmeasured confounding variables.
• Dataset is small in scale at 932.4 KB, indicating limited raw data or detailed patient-level variables.

Provenance

Source

figshare admin karger

Collection Method

Multi-center retrospective cohort study.

Time Range

2010-2022

Freshness

Data covers patient treatments from 2010 to 2022, with the study record last updated in April 2026.

Geography

United States and India